Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC
May 20th 2020Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.
Read More
Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer
February 28th 2018Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Read More